BUZZ - Jialong shares drop due to termination of late-stage cancer clinical trial
路透社2026/10/28 13:46Latest Updates
October 28 - ** Geron (GERN.O) shares fell by 20.6% to 91 cents
** The company will terminate its late-stage clinical trial (link) for a treatment drug targeting patients with a rare type of blood cancer
** The company had been testing a drug called Rytelo, used to treat a rare type of blood cancer known as myelofibrosis
** The company made this decision based on the recommendation of an independent data monitoring committee, which determined that the trial was unlikely to achieve its primary goal—overall survival
** The company stated it would conduct a detailed analysis of the data and release the research results at a later date
** “Geron had previously been evaluating external collaboration opportunities, but was reluctant to take action before knowing the trial results. Now that this uncertainty has been removed, business development may become an increasingly important source of flexibility for the product pipeline” — TD Cowen
** Including intraday fluctuations, the stock has fallen 31.8% so far this year
(To assist non-English speakers, Reuters provides automated translations of its reporting in several other languages. Automated translations may contain errors or lack necessary context; Reuters does not guarantee the accuracy of automated translations and provides them for readers’ convenience only. Reuters is not responsible for any damage or loss caused by the use of automated translation functions.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
GlaxoSmithKline endorses: anti-inflammatory biotech company Rezera (RZRA.US) plans to raise $200 millions through IPO, with a valuation of $254 millions
Rezera plans to raise $200 million in its IPO on Nasdaq, with an offering price between $11 and $13. GSK intends to subscribe for up to $25 million. The mid-point valuation is $254 million, and the company focuses on oral NLRP3 inhibitors.
BUZZ-3M India shares fall to 19-month low due to quarterly profit decline
Anthropic (ANT.US) to launch IPO roadshow next week, valuation may shrink from 1.5 trillion dollars to 1 trillion dollars! The AI capital feast faces a test.
After the AI sell-off, major investors are questioning whether Anthropic can go public at a $1.5 trillion valuation, or if it will be reduced to around $1 trillion. Fundraising may also decrease from $100 billion to $80 billion.
Hong Kong live music service provider Guitar Group applies for US IPO, aiming to raise $31 million
Guitar Group, a provider of music performance events, guitar-making workshops, and guitar repair services, submitted an application to the U.S. Securities and Exchange Commission (SEC) on Thursday, seeking to raise up to $31 million through an initial public offering (IPO).
Crypto prices
More
